GARDNER MARK A
SEC CIK 1955242 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DGX | Quest Diagnostics | SVP of Molecular Gen, Oncol | 4,673 | — | — | 5 | 2023-02-23 | 2024-09-24 |
Most active insiders at DGX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Davis J. E. | CEO, Pres, Dir | — | $17.08M |
| 2 | Doherty Catherine T. | EVP, Regional Businesses | — | $6.96M |
| 3 | PREVOZNIK MICHAEL E | SVP, GC | — | $6.69M |
| 4 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | — | $2.17M |
| 5 | Plewman Patrick | SVP for Diagnostic Services | — | $2.03M |
| 6 | DELANEY MARK E | SVP, Chief Commercial Off | — | $1.86M |
| 7 | PFEIFFER GARY M | Dir | — | $270.3K |
| 8 | Gregg Vicky B | Dir | — | $239.7K |
| 9 | Lassiter Wright III | Dir | — | — |
| 10 | Deppe Michael J | SVP, CAO, Corp. Ctrl | — | — |
GARDNER MARK A made no open-market trades at DGX in the last 12 months.
Transactions 5
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-26 | 2024-09-24 | DGX | Quest Diagnostics | GARDNER MARK A | SVP of Molecular Gen, Oncol | F - Tax | $155.70 | -120 | 4,673 | -3% | -$18.7K | |
| 2024-03-01 | 2024-02-28 | DGX | Quest Diagnostics | GARDNER MARK A | SVP of Molecular Gen, Oncol | F - Tax | $126.36 | -262 | 4,793 | -5% | -$33.1K | |
| D | 2024-02-16 | 2024-02-14 | DGX | Quest Diagnostics | GARDNER MARK A | SVP of Molecular Gen, Oncol | A - Grant | $0.00 | +2,250 | 5,055 | +80% | $0 |
| 2023-09-27 | 2023-09-25 | DGX | Quest Diagnostics | GARDNER MARK A | SVP of Molecular Gen, Oncol | F - Tax | $126.22 | -116 | 2,805 | -4% | -$14.6K | |
| D | 2023-02-27 | 2023-02-23 | DGX | Quest Diagnostics | GARDNER MARK A | SVP of Molecular Gen, Oncol | A - Grant | $0.00 | +1,919 | 2,921 | +192% | $0 |
Purchase Sale Sale after option exercise All abbreviations